Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

计划入组 1 人 · 首次发布于 2020 年 2 月 20 日

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

计划入组 13 人 · 首次发布于 2022 年 5 月 31 日

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

计划入组 32 人 · 首次发布于 2025 年 6 月 6 日

Acute Myeloid Leukemia(Advesya)

DCPS inhibitor (acute myeloid leukemia)

MYELOID THERAPEUTICS

United States

JAPAN ADULT LEUKEMIA STUDY GROUP

Japan

Bio-Path Holdings

United States

Leukemia Research Foundation funds UC study targeting RhoA in TP53-mutated AML

FDA Approves Ziftomenib, First-in-Class Targeted Therapy for NPM1-Mutated Acute Myeloid Leukemia

FDA Approves Ivosidenib Plus Azacitidine for IDH1-Mutated Acute Myeloid Leukemia